HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic … Continue reading →

HeartBeam (NASDAQ: BEAT) will host a conference call on May 13 at 4:30 p.m. Eastern to discuss financial results for the first quarter ended March 31, 2025. CEO Robert Eno and CFO Timothy Cruickshank will lead the call, which will include … Continue reading →

HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment. Results were presented by Dr. Thomas Deering of Piedmont Heart Institute … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a strategic collaboration with AccurKardia, a leader in ECG-based diagnostics. The partnership will integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s compact, cable-free 3D ECG … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company advancing cardiac care, has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram (“ECG”) synthesis software. The software is designed to assess cardiac rhythms and arrhythmias, … Continue reading →

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on enhancing cardiac care through advanced insights, will hold a conference call on November 7, 2024, at 4:30 p.m. ET to discuss third-quarter results and share updates on regulatory developments and ongoing … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic’ category at the HLTH global healthcare conference. The award highlights HeartBeam’s innovative … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has named a seasoned medtech leader as its new chief financial officer. According to the announcement, Timothy Cruickshank has accepted the role … Continue reading →